Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 2/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 2/20 | 1.00 |
| ▸ | CILK1 | Q9UPZ9 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 1.00 |
| ▸ | DDX42 | Q86XP3 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 0.98 |
| ▸ | CDK2 | P24941 | 12/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL290347 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL663220 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL29387962 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL29505152 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL663219 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL23683025 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL17348307 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL665749 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL31702788 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL291157 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640380-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | Piramal Enterprises Limited (IN) | 2013-09-25 | — | — | EP | claimed |
| WO-2012069972-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BREAST CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-31 | — | — | WO | claimed |
| WO-2012066508-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-24 | — | — | WO | claimed |
| EP-2640380-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | Piramal Enterprises Limited (IN) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012123889-A1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PANCREATIC CANCER | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012069972-A1 | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BREAST CANCER | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012066508-A1 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-24 | — | — | WO | disclosed |